Rapid COVID-19 Passive Therapy Response Platform

Informazioni relative al progetto

RapCo-19

ID dell’accordo di sovvenzione: 961845

DOI 10.3030/961845

Progetto chiuso

Data della firma CE 28 Luglio 2020

Data di avvio 1 Settembre 2020

Data di completamento 31 Maggio 2022

Finanziato da

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Costo totale € 4 500 000,00

Contributo UE € 2 500 000,00

Coordinato da

REMEDY BIOLOGICS LIMITED
Ireland

Risultati finali

Demonstrators, pilots, prototypes (3)

Proven pre-clinical safety and efficacy of the SARS-CoV-2 vaccine and antibody drug product

Preclinical studies demonstrating the safety and efficacy of passive therapy in rodent models Data will be shared with the EIC

Highly purified antibody therapy for preclinical studies

Characterised lead candidates will be expressed and antibody purified for the direct passive therapy in preclinical studies Sufficient purified antibodyprotein will be generated to ensure full preclinical studies can be performed

Antibody DNA sequence of lead candidate(s)

Recombinant antibody DNA and sequence information of lead candidates that can be provided to partners for cloningmanufacture in partner expression systems Providing recombinant DNA can provide rapid scaling through multiple partners

Open Research Data Pilot (1)

Deployment of SARS-Cov-2 antibody passive vaccine therapy

Remedy Biologics will partner with appropriate bigpharma and EU Government authorities to produce and deploy vaccines